4
Changes in Ownership
REGENERON PHARMACEUTICALS, INC. Filed Acc 0001968202-23-000004
EVP Finance CFO sold 1,190 shares at an average $823.20 ($979,605)
- EVP Finance CFO gave up 2,793 shares (to pay taxes)
- EVP Finance CFO acquired 3,800 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Landry Robert E · EVP Finance CFO
Table I: Non-derivative
20 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-03-27 | Exercise or conversion : show line 1 in the form 10b5-1 | +800 | $381.92 | $305,536 | 32,905 | D |
| 2023-03-27 | Shares withheld for taxes : show line 2 in the form 10b5-1 | −589 | $825.17 | $486,025 | 32,316 | D |
| 2023-03-27 | Exercise or conversion : show line 3 in the form 10b5-1 | +3,000 | $378.98 | $1,136,940 | 35,316 | D |
| 2023-03-27 | Shares withheld for taxes : show line 4 in the form 10b5-1 | −2,204 | $825.17 | $1,818,675 | 33,112 | D |
| 2023-03-27 | Sale : show line 5 in the form 10b5-1 | −39 | $819.47 | $31,959 | 33,073 | D |
| 2023-03-27 | Sale : show line 6 in the form 10b5-1 | −50 | $820.46 | $41,023 | 33,023 | D |
| 2023-03-27 | Sale : show line 7 in the form 10b5-1 | −48 | $821.39 | $39,427 | 32,975 | D |
| 2023-03-27 | Sale : show line 8 in the form 10b5-1 | −18 | $822.57 | $14,806 | 32,957 | D |
| Open-market sales · 1,190 sh · avg $823.20 · $979,605 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-03-27 | Exercise or conversion : show line 21 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −3,000 | 20,337 | D |
| 2023-03-27 | Exercise or conversion : show line 22 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −800 | 0 | D |
Loading xslF345X04/edgardoc.xml…